Document Detail

Mesigyna once-a-month combined injectable contraceptive: experience in Latin America.
MedLine Citation:
PMID:  10906501     Owner:  NLM     Status:  MEDLINE    
A phase III clinical study was carried out among 534 fertile Latin American women to evaluate cycle control, side effects, and contraceptive efficacy of a once-a-month combined injectable, Mesigyna, consisting of 50 mg norethisterone enanthate and 5 mg estradiol valerate. The pregnancy rate at 1 year was 0 per 100 woman-years for a total experience of 4688 woman-months. The overall discontinuation rate at one year was 17.9%. Discontinuation rate for bleeding problems was 5.1%. The Colombian women had a significant increase (p <0.001) in bleeding problems compared to other countries. The discontinuation rate for amenorrhea was 1.1%. There were no significant differences between the groups regarding discontinuation for other medical or non-medical reasons. Mean weight gain after one year of use was 1.02 kg. Mesigyna is an appropiate once-a-month injectable contraceptive for Latin American women since it is highly effective and its perception of normal menstrual bleeding is of importance in the Latin American population.
S Bassol; M C Cravioto; M Durand; R Bailon; S Carranza; J Fugarolas; R Gaona; L M Parada; C Celis; S Santoyo; J Garza-Flores; L Vazquez; C Lopez; C Gurucharri; J Novelli; H Carneiro de Oliveira; J Mendez; M E de Andrade; N R de Mello; K de Melo; E Chada; M E Yassle; A Castañeda; P Gomez; C Arboleda; L Trujillo; R Bucheli; I Hidalgo; R Olavide; J Parejarios; J Succar; R Reyes-Marquez; G Albrecht
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Contraception     Volume:  61     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-08-17     Completed Date:  2000-08-17     Revised Date:  2009-10-06    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  309-16     Citation Subset:  IM; J    
Centro de Investigacion Biomedica Universidad, Autonoma de Coahuila, Mexico.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amenorrhea / chemically induced
Blood Pressure
Contraceptive Agents, Female* / administration & dosage,  adverse effects
Drug Combinations
Estradiol / analogs & derivatives*
Latin America
Norethindrone / analogs & derivatives*
Uterine Hemorrhage / chemically induced
Weight Gain
Reg. No./Substance:
0/Contraceptive Agents, Female; 0/Drug Combinations; 0/estradiol, norethindrone drug combination; 50-28-2/Estradiol; 68-22-4/Norethindrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and side effects of immediate postcoital levonorgestrel used repeatedly for contraception.U...
Next Document:  Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and...